Utility of Flow Cytometry in Bone Marrow-Involved Non-Hematological Malignancies
Hematology Reports · 23.10.2026 · 18 (6) · 78
DOI: 10.3390/hematolrep18060078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 23.10.2026. Verfasst von Osamu Imataki und 2 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
The presence of cancer cells in the bone marrow can cause blood cell abnormalities; when bone marrow metastasis is suspected, aspiration is performed to test for hematological disorders. However, the usefulness of combining cell surface markers with flow cytometry analysis (FCM) in this situation has not been verified.
Methods
To review the clinical efficacy of FCM for detecting bone marrow involvement in cancer patients, we searched articles in PubMed using the keywords [bone marrow involvement] × [flow cytometry] among cancer types. To present an example case, we examined the bone marrow of cancer patients with cytopenia and analyzed the characteristics of the cell surface antigens. Bone marrow aspiration was performed from the iliac bone, and smear specimens were examined using May–Giemsa staining. We used a Beckman Coulter NAVIOS for FCM analysis and routine panels of myeloid and lymphoid neoplasms for surface marker analysis.
Results
We reviewed the reported flow cytometric characteristics of bone marrow involvement in sarcomas, germ cell tumors, and carcinomas. Neuroblastoma and rhabdomyosarcoma commonly demonstrated CD45-negative/CD56-positive immunophenotypes, while epithelial markers such as EpCAM or cytokeratins were useful in selected carcinoma subtypes. FCM facilitated the identification of suspicious non-hematopoietic cell populations within bone marrow specimens, particularly when conventional morphological findings were subtle or equivocal. However, the diagnostic utility of individual markers varied among tumor types, and definitive lineage assignment required integration with morphology, histology, immunohistochemistry, and clinical findings.
Conclusions
The diagnostic utility of FCM in detecting bone marrow involvement is still under investigation, and it is used to supplement microscopic diagnosis. CD56 or epithelial markers in the CD45-negative fraction are considered useful markers in some types of cancers (neuroblastoma, rhabdomyosarcoma, gastric cancer, and small-cell lung cancer) for detecting abnormal cells that have spread from other primary sites. In several cancer types (germ cell tumors, breast cancer, non-small-cell lung cancer, and urinary tract cancer), the standard FCM markers are not present. This narrative review is explicit in its educational point, which is based on practical cases.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Imataki, O., Takeuchi, A., & Uemura, M. (2026). Utility of Flow Cytometry in Bone Marrow-Involved Non-Hematological Malignancies. Hematology Reports, 18(6), 78. https://doi.org/10.3390/hematolrep18060078
Vancouver
Imataki O, Takeuchi A, Uemura M. Utility of Flow Cytometry in Bone Marrow-Involved Non-Hematological Malignancies. Hematology Reports. 2026;18(6):78. doi:10.3390/hematolrep18060078
BibTeX
@article{Imataki2026,
author = {Imataki, Osamu and Takeuchi, Akihiro and Uemura, Makiko},
title = {Utility of Flow Cytometry in Bone Marrow-Involved Non-Hematological Malignancies},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {6},
pages = {78},
doi = {10.3390/hematolrep18060078}
}
EUVIMED